Connetics Announces 2005 Analyst and Investor Day in New York City; Ev

    Business Editors

    PALO ALTO, Calif.--(BUSINESS WIRE)--March 10, 2005--Connetics Corporation (Nasdaq: CNCT), a specialty pharmaceutical company that develops and commercializes dermatology products, today announced that it will host its Analyst and Investor Day on April 14, 2005 at The Mandarin Oriental Hotel in New York. The event will be broadcast live over the Internet including presentation slides beginning at approximately 10:30 a.m. Eastern Time.
    Connetics management will review key updates on areas encompassing commercial activities, marketed products, product pipeline and financial highlights. In addition to presentations by management, the event will feature a presentation from a leading physician expert in the field of dermatology. Investment professionals interested in attending Connetics' 2005 Analyst and Investor Day in New York City, should contact Heather LeDue at 650-843-2863 or hledue@connetics.com.
    To access the presentations via the Internet, go to the investor relations section of www.connetics.com. A replay of the event will be available for 30 days.

    About Connetics

    Connetics Corporation is a specialty pharmaceutical company focused on the development and commercialization of innovative therapeutics for the dermatology market. Connetics has branded its proprietary foam drug delivery vehicle VersaFoam(R). The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%, Luxiq(R) (betamethasone valerate) Foam, 0.12%, Soriatane(R) (acitretin) capsules and Evoclin(TM) (clindamycin) Foam, 1%. Connetics is developing Velac(R) (a combination of 1% clindamycin and 0.025% tretinoin) Gel, for treating acne, and Desilux(TM) (desonide) VersaFoam-EF, 0.05% a low-potency topical steroid formulated to treat atopic dermatitis. Connetics' product formulations aim to improve the management of dermatological diseases and provide significant product differentiation. In Connetics' marketed products, these formulations have earned wide acceptance by both physicians and patients due to their clinical effectiveness, high quality and cosmetic elegance. For more information about Connetics and its products, please visit www.connetics.com.

    Press Release Code: (CNCT-G)

--30--WG/sf*

CONTACT: Connetics Corporation Patrick O'Brien, 650-739-2950 (Director, Investor Relations) pobrien@connetics.com or Lippert/Heilshorn & Associates Ina McGuinness or Bruce Voss, 310-691-7100 imcguinness@lhai.com

KEYWORD: CALIFORNIA NEW YORK INDUSTRY KEYWORD: MEDICAL PHARMACEUTICAL CONFERENCE CALLS SOURCE: Connetics Corporation

Copyright Business Wire 2005